Advanced Accelerator Applications

AAA announces Ph3 NETTER-2 study with Lutathera as 1st Line in advanced GEP-NET

The NETTER-2 study is a Phase III clinical trial evaluating Lutathera's efficacy and safety in treating Grade 2 and 3 advanced GEP-NETs. The primary objective is to prolong Progression Free Survival in patients with high proliferation rate tumors.

SourceAdvanced Accelerator Applications·DateMar 25, 2020

AAA announces first patients dosed in 2 clinical studies with PSMA-R2 for prostate cancer

Two Phase I/II clinical studies, PROter and PROfind, evaluate the safety and efficacy of radiolabeled PSMA-R2 for prostate cancer treatment. The trials assess tumor activity and patient response to treatment.

SourceAdvanced Accelerator Applications·DateJun 21, 2018